A-3 Price List_Lisraya - TIBs - NA.xlsx
XLSX spreadsheet 45 KB Posted
- Solicitation number
- HT9402-26-Q-9404
- Issued by
-
Defense Health Agency
About this file
This is a price list template for the Department of War (DoW) Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) and Uniform Formulary Additional Discount Program (ADP) for Targeted Immunomodulatory Biologics scheduled for the November 4-5, 2026 P&T Committee meeting. The quote submission deadline is October 26, 2026. The document covers ten newly approved drugs within the Targeted Immunomodulatory Biologics class and requires manufacturers to submit pricing information across multiple formulary scenarios and points of service, including Military Treatment Facilities (MTF), Mail Order, and TRICARE Retail. Pricing submission requirements include: BPA pricing per NDC package size and per unit for both Uniform Formulary (after step therapy) and Non-Formulary scenarios; ADP pricing based on either non-FAMP (Federal Ceiling Price) calculations with additional refund percentages or Wholesale Acquisition Cost (WAC) discounts for TRICARE Retail tiers (Tier 2 and Tier 3, after step therapy). The document notes that step therapy will apply with grandfathering provisions, requiring new patients to complete adequate trials of step-preferred agents before access to non-step-preferred agents at any point of service.
Manufacturers are instructed to submit the Quote Review Checklist and fully executed signature pages along with quote information, with pricing per unit of measure remaining constant across all available package sizes within each dispensing venue. The pricing templates contain multiple appendices for both BPA and ADP programs, with the ADP appendices distinguishing between non-FAMP-based refund calculations (with current annual Federal Ceiling Price references and standard refund calculations) and WAC-based discount structures. All data on the submission sheets is subject to use and disclosure restrictions per the document's title page restrictions.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| A-3 Price List_Adquey-Atopic-Topical Agents.xlsx | XLSX spreadsheet | |
| A-3 Price List_Clotic-Antifungals-NA.xlsx | XLSX spreadsheet | |
| A-3 Price List_Etcamah-Breast Canc Agt-Estrogen Recptr Antag.xlsx | XLSX spreadsheet | |
| A-3 Price List_Langlara-Insulins-Basal.xlsx | XLSX spreadsheet | |
| A-3 Price List - Nuzolvence -Antibiotics - NA.xlsx | XLSX spreadsheet | |
| A-3 Price List - Rezenopy - Alcohol Deterrents-Narcotic Antag.xlsx | XLSX spreadsheet | |
| FAR 52-225-6-Certificate.pdf | ||
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| A-3 Price List_Armlupeg-White Blood Cell Stim-Pegfilgrastims.xlsx | XLSX spreadsheet | |
| A-3 Price List_Bixlenvo-Antiretrovirals-Combinations.xlsx | XLSX spreadsheet | |
| A-3 RFQ HT9402-26-Q-9404 NAD.pdf | ||
| A-3 Price List - Beqalzi - Onc Agents - Non-BTKI CLL-SLP.xlsx | XLSX spreadsheet | |
| A-3 Price List - Mimrylo - Hematological Agents - NA.xlsx | XLSX spreadsheet | |
| A-3 Price List_Rasonque-Oncological Agents-RAS Inhibitors.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf |
Show all 15
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 |
| Formulary Notes | |||
| Class Note(s): Step will apply. |
Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step | 1 or more | NO QUOTE | |||
| 20144TGXXNFAS1M | Non-Formulary | ||||
| After Step | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 |
| Formulary Notes | |||
| Class Note(s): Step will apply. |
Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 |
| Formulary Notes | |||
| Class Note(s): Step will apply. |
Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step | 1 or more | ||||
| 20144TGXX1T3AS1M | Tier 3 | ||||
| After Step | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .